Screener
Crinetics Pharmaceuticals CRNX Total Revenue
Total Revenue at other companies
Segments
Other financials
Where this comes from
Reported directly by Crinetics Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The source filing: Crinetics Pharmaceuticals’s 10-Q, filed May 7, 2026.
- Filed
- May 7, 2026, 4:21 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001658247-26-000040
| Line item | Three months ended March 31, 2026 | Three months ended March 31, 2025 |
|---|---|---|
| Revenue: | ||
| Product revenue, net | $10,306 | — |
| Collaboration and license revenue | 428 | 361 |
| Total revenue | 10,734 | 361 |
| Operating expenses: | ||
| Cost of product revenue | 200 | — |
| Research and development | 100,081 | 76,240 |
| Selling, general and administrative | 50,831 | 35,526 |
Item 1. Condensed Consolidated Financial Statements (Unaudited)
FAQ
- What is Crinetics Pharmaceuticals's total revenue?
- Crinetics Pharmaceuticals (CRNX) reported total revenue of $10.73M in Q1 2026.
- How has Crinetics Pharmaceuticals's total revenue changed year-over-year?
- Crinetics Pharmaceuticals's total revenue increased by 2873.4% year-over-year, from $361K to $10.73M.
- What is the long-term trend for Crinetics Pharmaceuticals's total revenue?
- Over 4 years (2021 to 2025), Crinetics Pharmaceuticals's total revenue has grown at a 63.5% compound annual growth rate (CAGR), from $1.08M to $7.7M.
- What does total revenue mean?
- The aggregate of all revenue from the company's operations — the top line from which all profitability metrics are derived.
Ask your AI about Crinetics Pharmaceuticals's total revenue.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude